keyword
MENU ▼
Read by QxMD icon Read
search

HPV, Cervical Cancer, Gardasil

keyword
https://www.readbyqxmd.com/read/29551226/can-a-single-dose-of-human-papillomavirus-hpv-vaccine-prevent-cervical-cancer-early-findings-from-an-indian-study
#1
Rengaswamy Sankaranarayanan, Smita Joshi, Richard Muwonge, Pulikottil Okkuru Esmy, Partha Basu, Priya Prabhu, Neerja Bhatla, Bhagwan M Nene, Janmesh Shaw, Usha Rani Reddy Poli, Yogesh Verma, Eric Zomawia, Sharmila Pimple, Massimo Tommasino, Michael Pawlita, Tarik Gheit, Tim Waterboer, Peter Sehr, Madhavan Radhakrishna Pillai
BACKGROUND: Human papillomavirus (HPV) vaccination is a major strategy for preventing cervical and other ano-genital cancers. Worldwide HPV vaccination introduction and coverage will be facilitated if a single dose of vaccine is as effective as two or three doses or demonstrates significant protective effect compared to 'no vaccination'. METHODS: In a multi-centre cluster randomized trial of two vs three doses of quadrivalent HPV vaccination (GARDASIL©) in India, suspension of the vaccination due to events unrelated to the study led to per protocol and partial vaccination of unmarried 10-18 year old girls leading to four study groups, two by design and two by default...
March 15, 2018: Vaccine
https://www.readbyqxmd.com/read/29474934/design-and-statistical-considerations-for-studies-evaluating-the-efficacy-of-a-single-dose-of-the-human-papillomavirus-hpv-vaccine
#2
Joshua N Sampson, Allan Hildesheim, Rolando Herrero, Paula Gonzalez, Aimee R Kreimer, Mitchell H Gail
Cervical cancer is a leading cause of cancer mortality in women worldwide. Human papillomavirus (HPV) types 16 and 18 cause about 70% of all cervical cancers. Clinical trials have demonstrated that three doses of either commercially available HPV vaccine, Cervarix ® or Gardasil ®, prevent most new HPV 16/18 infections and associated precancerous lesions. Based on evidence of immunological non-inferiority, 2-dose regimens have been licensed for adolescents in the United States, European Union, and elsewhere...
May 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29327306/strengthening-the-case-for-gender-neutral-and-the-nonavalent-hpv-vaccine
#3
REVIEW
Justin M Hintze, James P O'Neill
PURPOSE: The purpose of this review is to highlight the benefits of gender-neutral and the nonavalent human papillomavirus vaccination. Human papillomavirus infection is the most commonly sexually transmitted disease and is known to cause several types of cancers, including cervical, vulvar, vaginal, penile, oropharyngeal, anal, and rectal. 5% of cancers every year are attributable to human papillomavirus infection, with cervical cancer the most common and oropharyngeal cancer estimated to surpass the incidence of cervical cancer by 2020...
April 2018: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/29273004/impact-of-hpv-vaccination-with-gardasil%C3%A2-in-switzerland
#4
Martine Jacot-Guillarmod, Jérôme Pasquier, Gilbert Greub, Massimo Bongiovanni, Chahin Achtari, Roland Sahli
BACKGROUND: Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomaviruses (HPV), has been offered to 11-14 year-old schoolgirls in Switzerland since 2008. To evaluate its success and its potential impact on cervical cancer screening, HPV genotypes were examined in 18-year-old girls five years later (sub-study 1) and in outpatients participating to cervical cancer screening before and after vaccine implementation (sub-study 2). METHODS: For sub-study 1, 3726 females aged 18 in 2013 were invited to fill a questionnaire on personal demographics and HPV risk factors and to provide a self-collected cervicovaginal sample for HPV genotyping and Chlamydia trachomatis PCR...
December 22, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29128382/bad-news-the-influence-of-news-coverage-and-google-searches-on-gardasil-adverse-event-reporting
#5
Kate Faasse, Jarry T Porsius, Jonathan Faasse, Leslie R Martin
BACKGROUND: Human papilloma virus vaccines are a safe and effective tool for reducing HPV infections that can cause cervical cancer. However, uptake of these vaccines has been suboptimal, with many people holding negative beliefs and misconceptions. Such beliefs have been linked with the experience of unpleasant side effects following medical treatment, and media coverage may heighten such concerns. METHODS: The present study sought to assess the influence of news coverage (number of news articles per month) on adverse event reporting in response to Gardasil vaccination in New Zealand over a 7...
December 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28939477/a-novel-candidate-hpv-vaccine-ms2-phage-vlp-displaying-a-tandem-hpv-l2-peptide-offers-similar-protection-in-mice-to-gardasil-9
#6
Lukai Zhai, Julianne Peabody, Yuk-Ying Susana Pang, John Schiller, Bryce Chackerian, Ebenezer Tumban
Human papillomaviruses (HPVs) cause approximately 5% of cancer cases worldwide. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. Gardasil-9, the most recent HPV vaccine, is predicted to offer protection against the HPV types that cause ∼90% of cervical cancer, 86% of HPV-associated penile cancers, and ∼93% of HPV-associated head & neck cancers. As an alternative to Gardasil-9, we developed and tested a novel candidate vaccine targeting conserved epitopes in the HPV minor capsid protein, L2...
November 2017: Antiviral Research
https://www.readbyqxmd.com/read/28855937/immunization-of-mice-by-a-multimeric-l2-based-linear-epitope-17-36-from-hpv-type-16-18-induced-cross-reactive-neutralizing-antibodies
#7
Farhad Motavalli Khiavi, Arash Arashkia, Maryam Nasimi, Mehdi Mahdavi, Majid Golkar, Farzin Roohvand, Kayhan Azadmanesh
Current licensed and commercially available prophylactic human papillomavirus (HPV) vaccines (Cervarix and quadrivalent/nine valents Gardasil) are based on major capsid protein L1 virus-like particles (VLPs) production which are expensive and type specific. Minor capsid L2-RG1 linear epitope (17-36) is a known candidate for induction of cross-neutralizing antibodies to develop low-cost pan-HPV vaccines. Herein, we report construction and expression of a three tandem repeats of L2-RG1 derived from HPV16 and 18 fused with the same head to tail pattern (HPV16:17-36×3+ HPV18:17-36×3; hereafter termed dual-type fusion L2 peptide) in E...
August 2017: Research in Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28845336/elimination-of-cancer-health-disparities-through-the-acceleration-of-hpv-vaccines-and-vaccinations-a-simplified-version-of-the-president-s-cancer-panel-report-on-hpv-vaccinations
#8
Eva McGhee, Hill Harper, Adaku Ume, Melanie Baker, Cheick Diarra, John Uyanne, Sebhat Afework, Keosha Partlow, Lucy Tran, Judith Okoro, Anh Doan, Karen Tate, Mechelle Rouse, Meidrah Tyler, Kamilah Evans, Tonya Sanchez, Ishmum Hasan, Enijah Smith-Joe, Jasmine Maniti, Liliana Zarate, Camille King, Antoinette Alugbue, Chiamaka Opara, Bileko Wissa, Joanne Maniti, Roland Pattillo
The human papillomavirus (HPV) is a major public health concern affecting both females and males. HPV is associated with cervical, anal, head and neck cancers. About 99% of all cervical cancers are related to HPV. HPV vaccines, Gardasil, Cervarix, and Gardasil 9 are used in the primary prevention of HPV related cancers. Gardasil and Gardasil 9 are available for use in both females and males ages 9 to 26, while Cervarix is available for females ages 9 to 25. Gardasil 9 was approved by the FDA for prevention against additional HPV types...
June 2017: Journal of Vaccines & Vaccination
https://www.readbyqxmd.com/read/28720462/a-novel-trivalent-hpv-16-18-58-vaccine-with-anti-hpv-16-and-18-neutralizing-antibody-responses-comparable-to-those-induced-by-the-gardasil-quadrivalent-vaccine-in-rhesus-macaque-model
#9
Fei Yin, Yajun Wang, Na Chen, Dunquan Jiang, Yefeng Qiu, Yan Wang, Mei Yan, Jianping Chen, Haijiang Zhang, Yongjiang Liu
Persistent infection with human papillomavirus (HPV) is a key factor in the development of precancerous lesions and invasive cervical cancer. Prophylactic vaccines to immunize against HPV are an effective approach to reducing HPV related disease burden. In this study, we investigated the immunogenicity and dosage effect of a trivalent HPV 16/18/58 vaccine (3vHPV) produced in Escherichia coli (E.coli), with Gardasil quadrivalent vaccine (4vHPV, Merck & Co.) as a positive control. Sera collected from rhesus macaques vaccinated with three dosage formulations of 3vHPV (termed low-, mid-, and high-dosage formulations, respectively), and the 4vHPV vaccine were analyzed by both Pseudovirus-Based Neutralization Assay (PBNA) and Enzyme-Linked Immunosorbent Assay (ELISA)...
June 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/28701899/cost-effectiveness-analysis-of-the-nine-valent-hpv-vaccine-in-italy
#10
Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Giacomo Plazzotta, Mathieu Uhart, Alessandro Rinaldi, Nathalie Largeron
BACKGROUND: In Italy HPV vaccination with the quadrivalent vaccine (Gardasil(®)) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9(®)) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV positive cancers, over 80% of high-grade precancerous lesions and 90% of genital warts caused by HPV types 6/11. METHODS: A dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Italian setting and used to estimate costs and QALYs associated with vaccination strategies...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28699820/expanded-strain-coverage-for-a-highly-successful-public-health-tool-prophylactic-9-valent-human-papillomavirus-vaccine
#11
Zhigang Zhang, Jun Zhang, Ningshao Xia, Qinjian Zhao
Human papillomavirus is considered the causative factor for cervical cancer, which accounts for approximately 5% of the global cancer burden and more than 600,000 new cases annually that are attributable to HPV infection worldwide. The first-generation prophylactic HPV vaccines, Gardasil® and Cervarix®, were licensed approximately a decade ago. Both vaccines contain the most prevalent high-risk types, HPV16 and 18, which are associated with 70% of cervical cancer. To further increase the type coverage, 5 additional oncogenic HPV types (31, 33, 45, 52 and 58) were added to the existing Gardasil-4 to develop a 9-valent HPV vaccine (9vHPV), Gardasil 9®, increasing the potential level of protection from ∼70% to ∼90%...
October 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28506297/cervical-cancer-treatment-costs-and-cost-effectiveness-analysis-of-human-papillomavirus-vaccination-in-vietnam-a-prime-modeling-study
#12
Hoang Van Minh, Nguyen Thi Tuyet My, Mark Jit
BACKGROUND: Cervical cancer is currently the leading cause of cancer mortality among women in South Vietnam and the second leading cause of cancer mortality in North Vietnam. Human papillomavirus (HPV) vaccination has the potential to substantially decrease this burden. The World Health Organization (WHO) recommends that a cost-effectiveness analysis of HPV vaccination is conducted before nationwide introduction. METHODS: The Papillomavirus Rapid Interface for Modeling and Economics (PRIME) model was used to evaluate the cost-effectiveness of HPV vaccine introduction...
May 15, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28442134/hpv-vaccines-a-review-of-the-first-decade
#13
REVIEW
Diane M Harper, Leslie R DeMars
Pre-adolescent girls (9-15years) have the option of receiving a two dose HPV vaccine series at either a six month or one year interval to provide protection from HPV 16, the most prevalent type associated with cervical cancers, as well as several other less prevalent types. This series of vaccinations is highly likely to protect her from HPV infection until she enters the routine screening program, whether that be primary HPV testing or a combination of HPV testing and cytology. The two dose program has been recommended by the World Health Organization (WHO) since 2015...
July 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27771183/manufacturing-costs-of-hpv-vaccines-for-developing-countries
#14
Chaevia Clendinen, Yapei Zhang, Rebecca N Warburton, Donald W Light
BACKGROUND: Nearly all of the 500,000 new cases of cervical cancer and 270,000 deaths occur in middle or lower income countries. Yet the two most prevalent HPV vaccines are unaffordable to most. Even prices to Gavi, the Vaccine Alliance, are unaffordable to graduating countries, once they lose Gavi subsidies. Merck and Glaxosmithkline (GSK) claim their prices to Gavi equal their manufacturing costs; but these costs remain undisclosed. We undertook this investigation to estimate those costs...
November 21, 2016: Vaccine
https://www.readbyqxmd.com/read/27737666/experiences-and-lessons-learned-from-29-hpv-vaccination-programs-implemented-in-19-low-and-middle-income-countries-2009-2014
#15
Joël Ladner, Marie-Hélène Besson, Etienne Audureau, Mariana Rodrigues, Joseph Saba
BACKGROUND: Cervical cancer is the greatest cause of age-weighted years of life lost in the developing world. Human papillomavirus (HPV) infection is associated with a high proportion of cervical cancers, and HPV vaccination may help to reduce the incidence of cancer. The aim of the study was to identify barriers, obstacles, and strategies and to analyze key concerns and lessons learned with respect to the implementation of HPV vaccination program in low- and middle-income countries. METHODS: The Gardasil Access Program (GAP) is a donation program established to enable organizations and institutions in eligible low-resource countries to gain operational experience designing and implementing HPV vaccination programs...
October 13, 2016: BMC Health Services Research
https://www.readbyqxmd.com/read/27644649/human-papillomavirus-infection-and-its-vaccines-knowledge-and-attitudes-of-primary-health-clinic-nurses-in-kelantan-malaysia
#16
K Jeyachelvi, S Juwita, D Norwati
BACKGROUND: Cervical cancer though preventable is still the leading cause of cancer death among women secondary to breast cancer. Persistent infection with HPV has been causally linked to the disease. A school based HPV vaccination program was introduced in late 2010 in Malaysia and nurse support is essential for its success. OBJECTIVES: To determine nurses knowledge and attitudes about HPV infection and its vaccines, and factors associated with their knowledge...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27503625/severe-somatoform-and-dysautonomic-syndromes-after-hpv-vaccination-case-series-and-review-of-literature
#17
REVIEW
Beniamino Palmieri, Dimitri Poddighe, Maria Vadalà, Carmen Laurino, Carla Carnovale, Emilio Clementi
Human papilloma virus (HPV) is recognized as a major cause for cervical cancer among women worldwide. Two HPV vaccines are currently available: Gardasil® and Cervarix® . Both vaccines enclose viral antigenic proteins, but differ as to the biological systems of culture and the adjuvant components. Recently, a collection of symptoms, indicating nervous system dysfunction, has been described after HPV vaccination. We retrospectively described a case series including 18 girls (aged 12-24 years) referred to our "Second Opinion Medical Network" for the evaluation of "neuropathy with autonomic dysfunction" after HPV vaccination...
February 2017: Immunologic Research
https://www.readbyqxmd.com/read/27366939/an-estimate-of-the-public-health-impact-and-cost-effectiveness-of-universal-vaccination-with-a-9-valent-hpv-vaccine-in-germany
#18
Nathalie Largeron, Karl Ulrich Petry, Jorge Jacob, Florence Bianic, Delphine Anger, Mathieu Uhart
INTRODUCTION: Since 2007, the German Standing Vaccination Committee recommends HPV vaccination for girls aged 12-17 with a 2- (Cervarix®) or 4-valent (Gardasil®) vaccine. A 9-valent vaccine (Gardasil 9®) recently received a European market authorization in 2015. METHODS: A dynamic transmission model was calibrated to the German setting and used to estimate costs and QALYs associated with vaccination strategies. RESULTS: Compared to the current vaccination program, the 9-valent vaccine extended to boys shows further reductions of 24% in the incidence of cervical cancer, 30% and 14% in anal cancer for males and females, as well as over a million cases of genital warts avoided after 100 years...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27329199/immunotherapy-for-human-papillomavirus-associated-disease-and-cervical-cancer-review-of-clinical-and-translational-research
#19
REVIEW
Sung Jong Lee, Andrew Yang, T C Wu, Chien Fu Hung
Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally...
September 2016: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/27137484/development-of-human-papillomavirus-hpv-vaccines-a-review-of-literature-and-clinical-update
#20
Vikrant Chadrakant Sangar, Balasaheb Ghongane, Gaurav Mathur
The casual relationship concerning Human papillomaviruses (HPV) and cervical cancer is already established. Therefore, such HPV-associated malignancies might be prevented by prophylactic HPV vaccines. From 2009, two prophylactic HPV L1 Virus-Like Particle vaccines namely, Gardasil®; - quadrivalent (Merck) and Cervarix™ - bivalent (GlaxoSmithKline) are widely commercially available. By Aug 2014, 58 countries had introduced HPV vaccination in their national immunization program; this has led to numerous publications on safety and real world effectiveness...
2016: Reviews on Recent Clinical Trials
keyword
keyword
19475
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"